February 2026 Options Now Available For Cardinal Health (CAH)

Cardinal Health (CAH) trades at $207.47 and the article outlines two option strategies: selling a $200 put (bid $3.10) would set an effective purchase price of $196.90 and is estimated to have a 67% chance of expiring worthless, yielding 1.55% (12.86% annualized) if it does. Alternatively, buying shares and selling a $210 covered call (bid $5.40) would generate a 3.82% total return to Feb 2026 if called, with a 51% chance of expiring worthless and a 2.60% (21.59% annualized) YieldBoost; implied volatilities are ~30% (put) and 28% (call) versus a 12‑month realized volatility of 26%.

Analysis

Market structure: The option quotes imply a skew where implied volatility (puts 30%, calls 28%) exceeds realized (~26%), favoring premium sellers and market-making flows. Short-dated directional risk is muted because Feb‑2026 option strikes ($200 put, $210 call) are near-the-money relative to $207.47, concentrating potential assignment risk around a narrow ±5% band. Net effect: income strategies (covered calls, cash-secured puts) benefit short-term yield-seekers while long-biased holders risk being called away or assigned at tight thresholds.

Risk assessment: Tail risks include an earnings or policy shock that gaps CAH >10% (assignment or forced exits), supply-chain disruption, or regulatory changes to drug distribution margins; such events would blow up short vol positions given calendar length to Feb‑2026. Immediate (days) risk is IV repricing around catalysts; short-term (weeks–months) is theta capture vs event risk; long-term (quarters) is fundamental margin pressure or secular reimbursement changes. Hidden dependency: option P/L is highly sensitive to IV compressions/expansions and dividend/repurchase announcements that change expected returns.

Trade implications: For capital-efficient income, selling the Feb‑2026 CAH $200 put for ~3.10 yields an effective buy basis $196.90 with a ~67% chance to keep premium — size at 1–3% notional per account and explicit buy-stop if CAH < $185. Covered-call sellers owning CAH can sell Feb‑2026 $210 for ~5.40 to lock a 3.8% gross return to expiry; roll/close if IV spikes >40% or price >$215. Use protective collars (buy $195 puts) or vertical debit spreads around earnings to limit tail risk rather than naked short gamma.

Contrarian angles: Consensus underweights the asymmetric edge from IV>realized — systematic selling may persist and compress returns if no shocks occur, making short‑premium attractive but crowded. Conversely, if regulators or earnings surprise, IV could gap higher and punish sellers — current market underprices that tail (>10% gap). Historical parallels: distributor reactions to reimbursement headlines in 2018–2019 created sharp >20% moves; thus option sellers must size for fat-tail scenarios.

Key Decisions for Investors

• Sell cash‑secured Feb‑2026 CAH $200 puts for ~3.10 (net cost basis $196.90) sized to 1–3% of portfolio equity; set automatic buy‑to‑close if CAH < $185 or if IV > 45% to limit tail exposure.
• If already long CAH at ~207, implement a buy‑write: sell Feb‑2026 $210 calls for ~5.40 to lock ~3.8% to expiry; plan to roll up-and-out to ~$220 strike if CAH > $215 before 60 days to preserve upside.
• If unwilling to accept assignment, deploy a collar: buy Feb‑2026 $195 puts (~pay up to preserve downside) financed by selling $210 calls, target net cost ~0–$2.50 and cap downside at ~5–6% over next 9–12 months.
• Relative/value: allocate 1% long CAH vs 1% short MCK (McKesson) only after verifying better margin guidance from CAH; trim positions if CAH underperforms by 7% within 30 trading days or if MCK materially outperforms.
• Monitor three triggers before adding size: CAH Q4 earnings release (expect +/- 6–8% post-print move), any federal reimbursement legislation within 90 days, and IV/realized convergence to <=26% — add size if IV compresses while fundamentals stable.